Insulet Corp
PODD
View Detailed Chart
241.930USD
-1.220-0.50%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
17.02BMarket Cap
69.05P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.50%
5 Days
-5.43%
1 Month
-17.81%
6 Months
-12.76%
Year to Date
-14.89%
1 Year
-15.90%
View Detailed Chart
TradingKey Stock Score of Insulet Corp
Currency: USD Updated: 2026-02-06Key Insights
Insulet Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 371.57.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Insulet Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Insulet Corp Highlights
StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.07B.
Fairly Valued
The company’s latest PE is 69.05, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.88M shares, decreasing 4.34% quarter-over-quarter.
Held by Mairs and Power
Star Investor Mairs and Power holds 1.13K shares of this stock.
Analyst Rating
Based on
28
analysts
Buy
Current Rating
371.565
Target Price
+52.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Insulet Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Insulet Corp Info
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Ticker SymbolPODD
CompanyInsulet Corp
CEOMcevoy (Ashley)
Websitehttps://www.omnipod.com
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69317.050
-653.080 (-0.93%)
282.580
+22.390 (+8.61%)
2054.890
+3.160 (+0.15%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
